Navigation Links
Circassia Announces Successful Results From Phase II Clinical Study of ToleroMune(R) Cat Allergy Therapy

OXFORD, England, November 20 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced positive results from a recently completed phase II clinical study of its ToleroMune(R) cat allergy therapy, which successfully identified the optimal dosing regimens to progress into late-stage development. The clinical trial, which was the first of its kind in the field of cat allergy immunotherapy, showed that Circassia's ToleroMune treatment was extremely well tolerated and greatly reduced sufferers' symptoms.

Circassia conducted the double-blind study in Canada, where 121 subjects with confirmed cat allergies were randomised to receive placebo or one of four different treatment regimes with standardised doses of ToleroMune. The volunteers were exposed to cat allergens (aerosolised dander) in an environmental exposure chamber for 3 hours each day on four consecutive days, both before and after treatment. At set time points the subjects scored their ocular and nasal symptoms to allow investigators to measure the effect of the ToleroMune treatment. This is the first trial of a cat allergy immunotherapy to use this validated approach.

The study's results demonstrate that ToleroMune therapy can dramatically reduce both nasal and ocular allergy symptom levels, and that the treatment effect grows as the duration of exposure increases and symptoms are at their greatest. The optimal regimen decreased total symptom scores by 67% compared with placebo. Throughout the study ToleroMune treatment was extremely well tolerated, with a safety profile similar to placebo. This contrasts with many traditional immunotherapies, which are associated with a range of local tolerability issues and sometimes severe and even life-threatening adverse events.

"These positive phase II results are extremely important for Circassia as they identify the optimal treatment regime to move into the final stages of development for our cat allergy therapy, and will prove invaluable as we progress our broader portfolio of ToleroMune products," said Steve Harris , Circassia's CEO. "We are particularly pleased that the ToleroMune treatment achieved such a marked improvement in ocular symptoms, which can be a particular problem in cat allergy. As well as benefiting patients, this effect scientifically validates the ToleroMune approach and its novel focus on generating regulatory T cells to shut down this type of IgE-mediated allergic response."

About Circassia

Circassia is a specialty biopharmaceutical company focused on the field of allergy. The company's range of allergy therapeutics utilises its proprietary T-cell epitope desensitisation technology, ToleroMune, in a short treatment regime without the need for adjuvants or other immune stimulators. Circassia's products offer potential major clinical benefits compared with existing therapies, and consequently have significant market opportunities. Over 150 million people suffer from allergic rhinitis in the US and Europe, and the current treatment market is approximately $12 billion per year.

ToleroMune technology has additional potential regulatory and supply chain benefits. The short peptides utilised in Circassia's products are manufactured chemically, in contrast to existing allergen immunotherapies, which are purified from natural sources. Circassia's approach applies the chemistry, manufacturing and control standards associated with conventional pharmaceuticals to immunotherapy. This fits with changes in the European regulatory environment, where authorities are increasingly treating allergen immunotherapies as pharmaceutical products, and requiring elimination of the batch-to-batch potency variability that is an intrinsic feature of many currrent treatments.

Circassia has a highly experienced management team with a proven track record in product development and commercialisation. Having successfully completed two fundraising rounds the company is backed by a syndicate of world-class venture capital and institutional investors, including Imperial Innovations, Lansdowne Partners, Goldman Sachs and Invesco Perpetual.

    For more information please visit


    Steve Harris
    Tel: +44-(0)1865-784574

    Rob Budge
    RJB Communications
    Tel: +44-(0)1865-760969
    Mobile: +44-(0)7710-741241

SOURCE Circassia Ltd

SOURCE Circassia Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. IVF Florida Announces New Patient Finance Solution for Fertility Treatments
2. Secretary Shinseki Announces Study of Vietnam-Era Women Veterans
3. Great Customer Service Just Got Better as Emedco Announces the Launch of their Completely Updated and Enhanced Website
4. Nationwide Imaging Services, Inc., Leader In Diagnostic Imaging Equipment, Announces The Creation Of New Business Division Nationwide Medical Equipment Services
5. Parascript Announces AccuDetect 3.0 Computer Aided Detection (CAD) Algorithms With Improved Performance for CAD Vendors and Manufacturers of Mammography Systems
6. Universal Health Services, Inc. Announces Stock Split and Cash Dividend Increase
7. GettingHired Announces Additional Funding for Continued Growth as Well as R&D of New Product for Long Term Disability and Workers Comp.
8. Ziosoft Announces the Appointment of Rob Royea, Vice President, Sales and Marketing
9. WAT-AAH!, The First Functional Bottled Water For Kids, Announces The Release of WATs-THE-WORD?!
10. Oncolytics Biotech(R) Inc. Announces Terms of Unit Offering
11. Albireo Announces Positive Clinical Data on A3309 in Patients with Chronic Idiopathic Constipation
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... the way that they are handling security in light of the recent terrorist attacks ... in an attempt to stop an attack from reaching U.S. soil. Especially around special ...
(Date:11/27/2015)... ... November 27, 2015 , ... An ... way to dispense prescription medications at home, so he invented the patent-pending ELECTRONIC ... and dispense prescription medications. In doing so, it could help to prevent potential ...
(Date:11/27/2015)... ... November 27, 2015 , ... The ... of USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with a ... component is distributed nationally, through a vast social media strategy and across a ...
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent with ... the 2016 Building Better Radiology Marketing Programs meeting will showcase some ... March 6, 2016, at Caesars Palace in Las Vegas with a pre-conference session ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you ... for not only fulfilling the needs of advisers and clients but going above ... and providing top-tier customer service. However, there's always room for improvement, which is ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... Países Bajos, November 26, 2015 ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... con la terapia fotodinámica de Bremachlorin para el cáncer ... enfoque combina la inmunoterapia con la terapia fotodinámica de ... Clinical Cancer Research . --> Clinical Cancer ...
(Date:11/26/2015)... 26, 2015 ... aanpak combineert immunotherapie met Bremachlorin-photodynamische therapie voor ... ) --> ... ) Uit ... Centrum (LUMC) blijkt ...
(Date:11/26/2015)... 3D bioprinting market is expected ... new report by Grand View Research Inc. Rising prevalence of ... kidney transplantation is expected to boost the market growth, as ... transplantation. --> 3D bioprinting market is expected ... new report by Grand View Research Inc. Rising prevalence of ...
Breaking Medicine Technology: